Miguel J Divo,Miguel A Martinez-Garcia,Monica Gonzalez,Francisco Campos-Rodriguez,Patricia Lloberes,Marta Marin-Oto,Marta Forner,David Sanz-Rubio,David Nieto,Bartolome R Celli,Jose M Marin,
{"title":"阻塞性睡眠呼吸暂停患者MACE或死亡风险及气道正压通气的影响。","authors":"Miguel J Divo,Miguel A Martinez-Garcia,Monica Gonzalez,Francisco Campos-Rodriguez,Patricia Lloberes,Marta Marin-Oto,Marta Forner,David Sanz-Rubio,David Nieto,Bartolome R Celli,Jose M Marin, ","doi":"10.1183/13993003.00519-2025","DOIUrl":null,"url":null,"abstract":"RATIONALE\r\nEvidence regarding the efficacy of positive airway pressure (PAP) therapy in reducing the risks of non-fatal major cardiovascular events (NF-MACE) and mortality in patients with obstructive sleep apnoea (OSA) remains controversial.\r\n\r\nOBJECTIVES\r\nThis study aims to quantify the impact of PAP therapy on these risks and develop a predictive risk estimator.\r\n\r\nMETHODS\r\nWe conducted a multicentre, observational, prospective study involving 5358 individuals diagnosed with OSA, with a median follow-up of 14 years (IQR 10-15 years). We derived and validated a risk estimator of NF-MACE (including myocardial infarction, stroke, revascularisation procedures, and congestive heart failure) and all-cause mortality, incorporating PAP adherence alongside clinical and sleep-related data.\r\n\r\nRESULTS\r\nThe cohort's mean (sd) for age was 55±11 years, the Body Mass Index 32.0±5.4 Kg·m-2, and an apnoea-hypopnea index (AHI) of 35 (±22) events/hour; 26% were females, and 1467 (37%) were PAP adherent. Over the follow-up period, 754 participants experienced NF-MACE, while 858 deaths were recorded. Significant predictors included prior cardiovascular events, non-HDL cholesterol ≥200 mg·dL-1, COPD diagnosis, AHI >30 events/hr, and age >60 years. PAP adherence was protective (OR 0.46; 95% CI: 0.38 to 0.56), and the absolute risk reduction varied depending on the baseline risk (median of 16%, IQR 12-18). The risk estimator yielded an AUROC of 0.75 and a Brier score of 0.17, with 64% sensitivity and 75% specificity.\r\n\r\nCONCLUSIONS\r\nPAP therapy is associated with long-term risk reduction of NF-MACE and mortality in OSA patients, while the developed risk estimator enhances clinical decision-making regarding therapy initiation.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"32 1","pages":""},"PeriodicalIF":21.0000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MACE or Death Risk in Obstructive Sleep Apnoea and the Effect of Positive Airway Pressure.\",\"authors\":\"Miguel J Divo,Miguel A Martinez-Garcia,Monica Gonzalez,Francisco Campos-Rodriguez,Patricia Lloberes,Marta Marin-Oto,Marta Forner,David Sanz-Rubio,David Nieto,Bartolome R Celli,Jose M Marin, \",\"doi\":\"10.1183/13993003.00519-2025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"RATIONALE\\r\\nEvidence regarding the efficacy of positive airway pressure (PAP) therapy in reducing the risks of non-fatal major cardiovascular events (NF-MACE) and mortality in patients with obstructive sleep apnoea (OSA) remains controversial.\\r\\n\\r\\nOBJECTIVES\\r\\nThis study aims to quantify the impact of PAP therapy on these risks and develop a predictive risk estimator.\\r\\n\\r\\nMETHODS\\r\\nWe conducted a multicentre, observational, prospective study involving 5358 individuals diagnosed with OSA, with a median follow-up of 14 years (IQR 10-15 years). We derived and validated a risk estimator of NF-MACE (including myocardial infarction, stroke, revascularisation procedures, and congestive heart failure) and all-cause mortality, incorporating PAP adherence alongside clinical and sleep-related data.\\r\\n\\r\\nRESULTS\\r\\nThe cohort's mean (sd) for age was 55±11 years, the Body Mass Index 32.0±5.4 Kg·m-2, and an apnoea-hypopnea index (AHI) of 35 (±22) events/hour; 26% were females, and 1467 (37%) were PAP adherent. Over the follow-up period, 754 participants experienced NF-MACE, while 858 deaths were recorded. Significant predictors included prior cardiovascular events, non-HDL cholesterol ≥200 mg·dL-1, COPD diagnosis, AHI >30 events/hr, and age >60 years. PAP adherence was protective (OR 0.46; 95% CI: 0.38 to 0.56), and the absolute risk reduction varied depending on the baseline risk (median of 16%, IQR 12-18). The risk estimator yielded an AUROC of 0.75 and a Brier score of 0.17, with 64% sensitivity and 75% specificity.\\r\\n\\r\\nCONCLUSIONS\\r\\nPAP therapy is associated with long-term risk reduction of NF-MACE and mortality in OSA patients, while the developed risk estimator enhances clinical decision-making regarding therapy initiation.\",\"PeriodicalId\":12265,\"journal\":{\"name\":\"European Respiratory Journal\",\"volume\":\"32 1\",\"pages\":\"\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Respiratory Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1183/13993003.00519-2025\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Respiratory Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/13993003.00519-2025","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
MACE or Death Risk in Obstructive Sleep Apnoea and the Effect of Positive Airway Pressure.
RATIONALE
Evidence regarding the efficacy of positive airway pressure (PAP) therapy in reducing the risks of non-fatal major cardiovascular events (NF-MACE) and mortality in patients with obstructive sleep apnoea (OSA) remains controversial.
OBJECTIVES
This study aims to quantify the impact of PAP therapy on these risks and develop a predictive risk estimator.
METHODS
We conducted a multicentre, observational, prospective study involving 5358 individuals diagnosed with OSA, with a median follow-up of 14 years (IQR 10-15 years). We derived and validated a risk estimator of NF-MACE (including myocardial infarction, stroke, revascularisation procedures, and congestive heart failure) and all-cause mortality, incorporating PAP adherence alongside clinical and sleep-related data.
RESULTS
The cohort's mean (sd) for age was 55±11 years, the Body Mass Index 32.0±5.4 Kg·m-2, and an apnoea-hypopnea index (AHI) of 35 (±22) events/hour; 26% were females, and 1467 (37%) were PAP adherent. Over the follow-up period, 754 participants experienced NF-MACE, while 858 deaths were recorded. Significant predictors included prior cardiovascular events, non-HDL cholesterol ≥200 mg·dL-1, COPD diagnosis, AHI >30 events/hr, and age >60 years. PAP adherence was protective (OR 0.46; 95% CI: 0.38 to 0.56), and the absolute risk reduction varied depending on the baseline risk (median of 16%, IQR 12-18). The risk estimator yielded an AUROC of 0.75 and a Brier score of 0.17, with 64% sensitivity and 75% specificity.
CONCLUSIONS
PAP therapy is associated with long-term risk reduction of NF-MACE and mortality in OSA patients, while the developed risk estimator enhances clinical decision-making regarding therapy initiation.
期刊介绍:
The European Respiratory Journal (ERJ) is the flagship journal of the European Respiratory Society. It has a current impact factor of 24.9. The journal covers various aspects of adult and paediatric respiratory medicine, including cell biology, epidemiology, immunology, oncology, pathophysiology, imaging, occupational medicine, intensive care, sleep medicine, and thoracic surgery. In addition to original research material, the ERJ publishes editorial commentaries, reviews, short research letters, and correspondence to the editor. The articles are published continuously and collected into 12 monthly issues in two volumes per year.